Rab44 regulates murine mast cell–driven anaphylaxis through kinesin-1–dependent secretory granule translocation
Cyril Longé(Inserm), Gaël Ménasché(Inserm), Alain Fischer(Inserm), Geneviève de Saint Basile(Inserm), Shamila Vibhushan(Centre National de la Recherche Scientifique), Ulrich Blank(Centre National de la Recherche Scientifique), Valère Desmeure(Inserm), Fernando E. Sepulveda(Centre National de la Recherche Scientifique), Mathieu Kurowska(Délégation Paris 5), Pierre David(Centre National de la Recherche Scientifique), Jian‐Dong Huang(Sun Yat-sen University), Manuela Bratti(Centre National de la Recherche Scientifique)
Cited by 12
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k